Alkermes, Inc. (NASDAQ:ALKS)
CAPS Rating:
A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.
A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.
Recs
Very high profit margin
Very low P/E
Very high forward P/E
Earnings expected to grow at a rate of 42% over the next 5 years.
Very little debt (LT Debt/Equity is .12)
I put this stock at $30-40 by sometime next year. (Brave I know)
Enjoy!
DH